Brokerages forecast that Neon Therapeutics Inc (NASDAQ:NTGN) will announce earnings of ($0.61) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Neon Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.80) and the highest estimate coming in at ($0.46). Neon Therapeutics reported earnings per share of ($0.67) in the same quarter last year, which suggests a positive year over year growth rate of 9%. The firm is scheduled to announce its next quarterly earnings results on Monday, November 11th.
According to Zacks, analysts expect that Neon Therapeutics will report full year earnings of ($2.51) per share for the current financial year, with EPS estimates ranging from ($3.18) to ($1.85). For the next year, analysts forecast that the firm will post earnings of ($2.28) per share, with EPS estimates ranging from ($4.17) to ($1.42). Zacks’ EPS averages are an average based on a survey of research analysts that cover Neon Therapeutics.
Neon Therapeutics (NASDAQ:NTGN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.01).
Neon Therapeutics stock traded up $0.01 during trading on Friday, reaching $2.20. 78,679 shares of the company were exchanged, compared to its average volume of 249,140. Neon Therapeutics has a 52-week low of $1.61 and a 52-week high of $9.70. The company has a market capitalization of $62.15 million, a P/E ratio of -0.40 and a beta of 1.49. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.13 and a quick ratio of 6.13. The stock’s 50 day simple moving average is $2.31 and its two-hundred day simple moving average is $4.10.
A number of hedge funds have recently bought and sold shares of the business. Morgan Stanley increased its stake in Neon Therapeutics by 10.8% during the second quarter. Morgan Stanley now owns 40,522 shares of the company’s stock worth $192,000 after acquiring an additional 3,939 shares during the last quarter. Vanguard Group Inc. increased its stake in Neon Therapeutics by 3.6% during the second quarter. Vanguard Group Inc. now owns 612,398 shares of the company’s stock worth $2,903,000 after acquiring an additional 21,387 shares during the last quarter. BlackRock Inc. increased its stake in Neon Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 765,850 shares of the company’s stock worth $3,631,000 after acquiring an additional 79,729 shares during the last quarter. Westfield Capital Management Co. LP acquired a new stake in Neon Therapeutics during the second quarter worth $149,000. Finally, Northern Trust Corp increased its stake in Neon Therapeutics by 8.5% during the second quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock worth $789,000 after acquiring an additional 12,971 shares during the last quarter. 67.10% of the stock is owned by institutional investors.
About Neon Therapeutics
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Featured Story: Trading Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.